{"id":"NCT00626028","sponsor":"Mallinckrodt","briefTitle":"Comparison of Inhaled Nitric Oxide and Oxygen in Participants Reactivity During Acute Pulmonary Vasodilator Testing","officialTitle":"Comparison of Supplemental Oxygen and Nitric Oxide for Inhalation Plus Oxygen in the Evaluation of the Reactivity of the Pulmonary Vasculature During Acute Pulmonary Vasodilator Testing","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-09","primaryCompletion":"2010-02","completion":"2010-02","firstPosted":"2008-02-29","resultsPosted":"2010-09-16","lastUpdate":"2019-12-20"},"enrollment":136,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"NONE","primaryPurpose":"DIAGNOSTIC"},"conditions":["Idiopathic Pulmonary Arterial Hypertension","Cardiomyopathy"],"interventions":[{"type":"DRUG","name":"Nitric Oxide for inhalation","otherNames":["INOmaxÂ®"]},{"type":"DRUG","name":"Oxygen","otherNames":[]},{"type":"DRUG","name":"Nitric Oxide plus Oxygen","otherNames":["Inhaled Nitric Oxide, Oxygen"]}],"arms":[{"label":"Nitric Oxide First, Oxygen Last","type":"EXPERIMENTAL"},{"label":"Oxygen First, Nitric Oxide Last","type":"EXPERIMENTAL"}],"summary":"The primary purpose of this study is to compare the number of participants with reversible pulmonary hypertension (vasoreactivity) due to nitric oxide for inhalation and oxygen as compared to 100% oxygen.","primaryOutcome":{"measure":"Number of Participants With Reversible Pulmonary Hypertension (Vasoreactivity)","timeFrame":"on Day 1","effectByArm":[{"arm":"Nitric Oxide First, Oxygen Last","deltaMin":28,"sd":null},{"arm":"Oxygen First, Nitric Oxide Last","deltaMin":16,"sd":null}],"pValues":[]},"eligibility":{"minAge":"4 Weeks","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":18,"countries":["United States","France","Netherlands","Spain","United Kingdom"]},"refs":{"pmids":["20405117"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":62},"commonTop":[]}}